# Nuclide record glioblastoma (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/glioblastoma/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "glioblastoma" ;
  schema:name "Glioma & glioblastoma"@en ;
  schema:description "Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."@en ;
  schema:url <https://nuclide.cc/indications/glioblastoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Glioblastoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q282142> ;
  schema:citation <https://en.wikipedia.org/wiki/Glioblastoma> ;
  nuclide:tag "cns", "spike" ;
  nuclide:related <https://nuclide.cc/indications/meningioma/> ;
  nuclide:targets <https://nuclide.cc/targets/b7h3/> ;
  nuclide:companies <https://nuclide.cc/companies/bms/> ;
  nuclide:institutions <https://nuclide.cc/institutions/penn-abramson/>, <https://nuclide.cc/institutions/heidelberg-nct/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/temozolomide/>, <https://nuclide.cc/drugs/temozolomide/> .